Efficacy News and Research

RSS

Disabling ItpkB enzyme improves function of Natural Killer cells

Researchers at The Scripps Research Institute (TRSI) are fueling the future of cancer treatment by improving a powerful tool in disease defense: the body's immune system. By revealing a novel but widespread cell signaling process, the scientists may have found a way to manipulate an important component of the immune system into more effectively fighting disease.

29 Nov 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

FDA approves Velomedix’s IDE to expand design of VELOCITY trial for heart attack

Velomedix, Inc., a venture-backed medical device company advancing the field of therapeutic hypothermia, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to expand the design of its VELOCITY pilot clinical trial.

29 Nov 2012

NovImmune commences NI-0101 Phase I clinical trial in arthritis

NovImmune SA initiated dosing in a Phase I clinical trial of NI-0101, a monoclonal antibody drug candidate targeting toll-like receptor-4 (TLR4).

29 Nov 2012

Macular pigment screener launched by Elektron Technology

Elektron Technology is launching a new, easy-to-use macular pigment screener (MPS II) that can quickly identify those most at risk of developing age-related macular degeneration (AMD).

28 Nov 2012

Factors increasing risk for pertussis in children evaluated

Research shows that children with pertussis infection are significantly less likely to have had all five diphtheria, tetanus, and acellular pertussis vaccine doses than uninfected children.

28 Nov 2012

Two-route drug combination best for horse joint pain

A combination of systemic nonsteroidal anti-inflammatory drugs plus intrasynovial glucocorticosteroids is superior to either medication alone in improving outcomes for lame horses with perisynovial pain of the metacarpophalangeal joint, report Dutch researchers.

28 Nov 2012

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and the tendency of cocaine to attract people who make poor life choices and then exacerbate impulsive behavior all make cocaine a vexing clinical condition.

28 Nov 2012

Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete.

28 Nov 2012

Yoga appears to be effective treatment for neck pain

According to published estimates, some 20 percent of the population suffers from chronic neck pain caused by a variety of structural dysfunctions in the neck, resulting in impaired quality of life and lost work time. A German study published in The Journal of Pain showed that yoga appears to be an effective treatment for neck pain and provides added benefits of improved psychological well being and quality of life.

28 Nov 2012

Microneedle-based measles vaccine can immunize against measles

Measles vaccine given with painless and easy-to-administer microneedle patches can immunize against measles at least as well as vaccine given with conventional hypodermic needles, according to research done by the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC).

28 Nov 2012

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.

28 Nov 2012

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread (tenofovir disoproxil fumarate).

28 Nov 2012

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.

27 Nov 2012

Philips Healthcare, UH to showcase latest medical technology at Cleveland Medical Mart

University Hospitals (UH) and Philips Healthcare are among a group of global leaders in healthcare to showcase the latest medical technology at the new Cleveland Medical Mart & Convention Center.

From Philips Healthcare 27 Nov 2012

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease is a very broad family of diseases. There are two main categories of liver disease:

27 Nov 2012

Grove professor to investigate personalized therapies against breast cancer

For some time, researchers have known about disparities in diagnoses and outcomes among breast cancer patients based on race and age. However, they have been challenged to develop a set of criteria that can be used to reliably target drug delivery mechanisms based on an individual patient's tumor.

27 Nov 2012

Tivantinib holds personalized therapy promise in HCC

Tivantinib is an effective second-line therapy for hepatocellular carcinoma patients whose tumors exhibit high MET receptor tyrosine kinase expression, indicate phase II study results.

26 Nov 2012

New therapeutic technique to repair and rebuild muscle for degenerative muscle disorders

A study published today in BioMed Central's open access journal Skeletal Muscle reports of a new therapeutic technique to repair and rebuild muscle for sufferers of degenerative muscle disorders. The therapy brings together two existing techniques for muscle repair - cell transplantation and tissue engineering - specifically, mesoangioblast stem cells delivered via a hydrogel cell-carrier matrix.

26 Nov 2012

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the initiation of a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (AD).

26 Nov 2012

Efficacy News and Research

Disabling ItpkB enzyme improves function of Natural Killer cells

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

FDA approves Velomedix’s IDE to expand design of VELOCITY trial for heart attack

NovImmune commences NI-0101 Phase I clinical trial in arthritis

Macular pigment screener launched by Elektron Technology

Factors increasing risk for pertussis in children evaluated

Two-route drug combination best for horse joint pain

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Yoga appears to be effective treatment for neck pain

Microneedle-based measles vaccine can immunize against measles

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

Philips Healthcare, UH to showcase latest medical technology at Cleveland Medical Mart

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Grove professor to investigate personalized therapies against breast cancer

Tivantinib holds personalized therapy promise in HCC

New therapeutic technique to repair and rebuild muscle for degenerative muscle disorders

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News